|
Psoriasis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our observed genetic interaction between PGF and VEGFA appears relevant to psoriasis, a disease with an angiogenic basis, and may influence development of an antiangiogenic approach to treatment.
|
31545526 |
2020 |
|
Psoriasis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Due to the effect of inhibiting production of VEGF, acitretin can effectively treat psoriasis.
|
31148871 |
2020 |
|
Psoriasis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Haplotype analysis suggests that the coexistence of the polymorphisms rs1799964 (TNF-α), rs2010963 (VEGF), rs833061 (VEGF), and rs6311 (5HT2A) may be a protective factor for psoriasis.
|
31148856 |
2020 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
PTHrP treatment of colon cancer cells promotes tumor associated-angiogenesis by the effect of VEGF.
|
30639585 |
2019 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
Serum vascular endothelial growth factor (VEGF) concentrations in colon cancer patients of the two groups were evaluated before and after chemotherapy.
|
31127996 |
2019 |
|
Malignant tumor of colon
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
This study aimed to evaluate the prognostic value of MVD in stage II and III colon cancer and its relation to tumour-stroma-percentage (TSP) and expression of HIF1A and VEGFA.
|
31420015 |
2019 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
Stimulation of colon cancer cells with VEGF-A and placental growth factor (PlGF) activated VEGF receptor-1 (VEGFR-1) and increased proliferation activity in an autocrine EGF/EGF receptor (EGF-R)-dependent manner.
|
31717527 |
2019 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
Chemokine receptor 7 targets the vascular endothelial growth factor via the AKT/ERK pathway to regulate angiogenesis in colon cancer.
|
31348616 |
2019 |
|
Psoriasis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Topical application or subcutaneous injection of the Fib3 antibody decreased Psoriasis Area and Severity Index and VEGF expression in imiquimod-treated mice.
|
30146751 |
2019 |
|
Psoriasis
|
0.600 |
Biomarker
|
disease |
BEFREE |
The objective of the study was to elucidate the mechanism by which siRNA-mediated silencing of KRT16 affects keratinocyte proliferation and vascular endothelial growth factor (VEGF) secretion in psoriasis through the extracellular signal-related kinase (ERK) signaling pathway.
|
30942529 |
2019 |
|
Psoriasis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Prolactin and the vascular endothelial growth factor seem to play a key role in psoriasis pathogenesis regarding hyperproliferation of epidermal keratinocytes and dermal vascular ectasia.
|
31384319 |
2019 |
|
Retinal Vein Occlusion
|
0.600 |
Biomarker
|
disease |
BEFREE |
The intravitreous injection of therapeutic proteins that neutralize vascular endothelial growth factor (VEGF) family members is efficient to reduce macular edema associated with wet age-related macular degeneration (AMD), retinal vein occlusion (RVO) and diabetic retinopathy (DR).
|
31173913 |
2019 |
|
Retinal Vein Occlusion
|
0.600 |
Biomarker
|
disease |
BEFREE |
IMPACT OF RETINAL ISCHEMIA ON FUNCTIONAL AND ANATOMICAL OUTCOMES AFTER ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN PATIENTS WITH RETINAL VEIN OCCLUSION.
|
31157714 |
2019 |
|
Retinal Vein Occlusion
|
0.600 |
Biomarker
|
disease |
BEFREE |
Association of Disorganization of Retinal Inner Layers With Visual Acuity Response to Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Secondary to Retinal Vein Occlusion.
|
30286219 |
2019 |
|
Retinal Vein Occlusion
|
0.600 |
Biomarker
|
disease |
BEFREE |
The top cited references mainly presented anti-VEGF medications on the management of RVO.
|
31528507 |
2019 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
A gene signature comprising LAMA1, ITGB1, ITGA2, CXCR4 and VEGFA has negative predictive value in colon cancer.
|
29907957 |
2018 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
The aim was to investigate the predictive value of postoperative VEGF serum concentration in patients undergoing surgery for colon cancer.
|
28683891 |
2018 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
We have used 20 Male wistar rats for the formation of colon cancer model and utilized albumin as carrier molecule for the delivery of siRNA against vascular endothelial growth factor receptor 2 (VEGF R2).
|
29709588 |
2018 |
|
Malignant tumor of colon
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We examined the effect of genipin on the intracellular level of HIF-1α and extracellular level of VEGF using the colon cancer cell line HCT116.
|
29630948 |
2018 |
|
Malignant tumor of colon
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
miR‑1 inhibits the progression of colon cancer by regulating the expression of vascular endothelial growth factor.
|
29845255 |
2018 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
The rationale for this therapeutic approach is based on the fact that antiangiogenic drugs can make tumors hypoxic, and thus more sensitive to PIM inhibitors.<b>Experimental Design:</b> Xenograft and orthotopic models of prostate and colon cancer were used to assess the effect of PIM activation on the efficacy of VEGF-targeting agents.
|
29084916 |
2018 |
|
Malignant tumor of colon
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We evaluated the efficacy of bevacizumab-based anti-angiogenesis in combination with PDT as well as the resulting VEGF levels and microvessel density (MVD) in a mouse model of human colon cancer.
|
29894822 |
2018 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
ALA PDT used in sublethal doses decreases release of VEGF in more aggressively growing SW620 colon cancer cell line in hypoxia-like conditions.
|
29079348 |
2018 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
We evaluated the influence of 28 single-nucleotide polymorphisms in 12 genes in the VEGF pathway on the prognosis of 347 patients with stage II-III colon cancer.
|
29282362 |
2018 |
|
Psoriasis
|
0.600 |
Biomarker
|
disease |
BEFREE |
In non-erythrodermic PF, VEGF positivity was similar to HI (P = 0.247), and lower than psoriasis (P = 0.049) and PV (P = 0.049).
|
29489039 |
2018 |